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Background: Among the solid tumors, human pancreatic ductal adenocarcinoma (PDAC) has the worst prognosis.
Gemcitabine is the standard first line of therapy for pancreatic cancer but has limited efficacy due to inherent or
rapid development of resistance and combining EGFR inhibitors with this regimen results in only a modest clinical
benefit. The goal of this study was to identify molecular targets that are activated during gemcitabine therapy
alone or in combination with an EGFR inhibitor.
Methods: PDAC cell lines were used to determine molecular changes and rates of growth after treatment with
gemcitabine or an EGFR inhibitor, AG1478, by Western blot analysis and MTT assays respectively. Flow cytometric
analysis was performed to study the cell cycle progression and rate of apoptosis after gemcitabine treatment.
ShRNA was used to knockdown STAT3. An in vivo orthotopic animal model was used to evaluate STAT3 as a target.
Immunohistochemical analysis was performed to analyze Ki67 and STAT3 expression in tumors.
Results: Treatment with gemcitabine increased the levels of EGFRTyr1068 and ERK phosphorylation in the PDAC cell
lines tested. The constitutive STAT3Tyr705 phosphorylation observed in PDAC cell lines was not altered by treatment
with gemcitabine. Treatment of cells with gemcitabine or AG1478 resulted in differential rate of growth inhibition.
AG1478 efficiently blocked the phosphorylation of EGFRTyr1068 and inhibited the phosphorylation of down-stream
effectors AKT and ERKs, while STAT3Tyr705 phosphorylation remained unchanged. Combining these two agents
neither induced synergistic growth suppression nor inhibited STAT3Tyr705 phosphorylation, thus prompting further
studies to assess whether targeting STAT3 improves the response to gemcitabine or AG1478. Indeed, knockdown of
STAT3 increased sensitivity to gemcitabine by inducing pro-apoptotic signals and by increasing G1 cell cycle arrest.
However, knockdown of STAT3 did not enhance the growth inhibitory potential of AG1478. In vivo orthotopic
animal model results show that knockdown of STAT3 caused a significant reduction in tumor burden and delayed
tumor progression with increased response to gemcitabine associated with a decrease in the Ki-67 positive cells.
Conclusions: This study suggests that STAT3 should be considered an important molecular target for therapy of
PDAC for enhancing the response to gemcitabine.
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PDAC is the fourth leading cause of cancer deaths in the
United States and has the worst prognosis of all solid
tumors. This year alone it is estimated that 38,460 of the
45,220 patients diagnosed with pancreatic cancer in the
United States will succumb to the disease [1]. Despite
advancements in the understanding of the genetics of
this disease and the use of combined chemotherapy
and targeted biological agents, the management of this
lethal malignancy remains one of the greatest onco-
logical challenges [2].
At the time of clinical presentation, most PDAC pa-
tients have advanced disease, either locally or with dis-
tant metastasis. Diagnosis at this late stage is likely due
to the absence of specific early signs and symptoms of
disease and the lack of reliable screening tests that
would allow for therapy at an earlier, potentially curable
stage [2]. Less than 20% of patients are diagnosed with
disease that is amenable for surgical intervention [3].
Sadly, about half of all patients with this disease die
within the first six months of diagnosis resulting in a
five-year survival rate of less than 5% [2].
The most striking genetic signature of PDAC is muta-
tions of codon-12 of the c-K-Ras gene and inactivating
mutations of INK4a, which occur in greater than 90% of
pancreatic tumors [4]. More than half of PDAC tumors
also exhibit loss of the functional tumor suppressor
gene, deleted in pancreatic cancer, locus 4 (DPC4), either
due to homozygous deletion or intragenic mutations,
and up to 75% of PDAC have a p53 mutation [4]. As
found with other solid tumors, PDAC shows aberrant
over-expression and/or constitutive activation of a num-
ber of growth factor receptors [5].
In 1997, Burris et al. [6] showed a survival benefit for
patients treated with gemcitabine compared with 5-
fluorouracil and since that time gemcitabine has been
the most used first-line therapy for the management of
PDAC [7]. The clinical response rate of PDAC to
gemcitabine is less than 25% and those tumors that
show an initial response generally develop resistance
during the course of therapy [8,9]. The rapid develop-
ment of resistance to gemcitabine may be mediated ei-
ther by molecular changes of tumor cells or due to
selection of a pre-existing sub-population of tumor cells
that are inherently resistant to chemotherapy. There
continue to be clinical trials that use gemcitabine in
combination with other chemotherapeutic or biologic
targeted agents. Erlotinib, an EGFR kinase inhibitor, in
combination with gemcitabine was approved as therapy
for PDAC on the basis of a survival benefit of approxi-
mately two weeks [10]. However, the enthusiasm for the
addition of erlotinib is dampened because of the high
cost, minimal increase in survival benefit, prevalence of
K-Ras mutations in most PDAC, and the potential foradditional toxicity. Recent studies [11,12] show that
FOLFIRINOX (5-fluorouracil, leucovorin, irinotecan, and
oxaliplatin) provides a short-term survival benefit over
gemcitabine; however, this regimen is restricted to patients
that have a good functional status. Thus, new therapeutic
targets and approaches are being sought to further im-
prove the survival of patients with PDAC.
Signal transducer and activation of transcription (STAT)
is a family of transcription factors known to mediate cyto-
kine and growth factor responses in a wide variety of cells
[13]. Among these proteins, STAT3 is often constitutively
activated and contributes to tumor progression and resist-
ance to apoptosis in both solid and hematological malig-
nancies [13,14]. We previously found that STAT3 was
constitutively activated in PDAC [15] and it plays a role in
the maintenance of a cancer stem cell phenotype [16,17].
This study investigated whether STAT3 may be an in-
dependent therapeutic target or may enhance response
to gemcitabine. In vitro studies show that constitu-
tive STAT3Tyr705 phosphorylation is not prevented by
inhibiting EGFR activation with an EGFR kinase inhibitor
(AG1478) or by treating cells with gemcitabine. Knocking
down STAT3 enhanced gemcitabine induced growth
inhibition in vitro by increasing G1 cell cycle arrest and
pro-apoptotic signals. Studies using an in vivo orthoto-
pic mouse model showed that knocking down STAT3
(BxPC3/shSTAT3) delayed tumor progression and in-
creased sensitivity to gemcitabine supporting the in vitro
findings that STAT3 may be a relevant target for impro-
ving therapeutic responses.
Results
Constitutive STAT3Tyr705 phosphorylation remains
relatively unchanged after gemcitabine treatment while
EGFRTyr1068 and ERK phosphorylation is increased
The effects of gemcitabine on the phosphorylation
levels of EGFR, STAT3, and ERKs were determined in
four PDAC cell lines. PANC-1, UK Pan-1, MIA PaCa-2
and BxPC3 cells were treated with increasing doses of
gemcitabine for 96 h and total cellular lysates were ana-
lyzed by Western blots (Figure 1). EGFRTyr1068 phos-
phorylation was modestly increased after gemcitabine
treatment although the levels of STAT3Tyr705 phos-
phorylation were relatively constant for all doses used.
Phosphorylation of ERKs was also increased in a dose-
dependent manner in three of the cell lines (PANC-1,
UK-Pan-1, MIA PaCa-2); whereas, ERKs were constitu-
tively phosphorylated in BxPC3 cells (Figure 1).
RON receptor kinase is a member of the c-Met family
and is reported to play a role in PDAC carcinogenesis.
Previous studies demonstrated that RON plays a role in
resistance to gemcitabine and suppression of RON
inhibited the expression of STAT3Tyr705 [18]. The four cell
lines examined in this study showed different expression
Figure 1 Constitutive STAT3Tyr705 phosphorylation is not inhibited by gemcitabine in PDAC cells. Exponentially growing PDAC cells were
treated with indicated concentrations of gemcitabine for 96 hrs and cellular lysates were subjected to Western blot analysis. The blots were
probed for indicated phospho-specific proteins and their respective total forms. As a loading control, human β-actin levels are shown.
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phorylation (Figure 1) is independent of RON expression
in some PDAC cells. Moreover, RON expression was
not appreciably changed by treatment with gemcitabine
(Figure 1).
EGFR inhibitor AG1478 differentially inhibited the growth
of PDAC cells while constitutive STAT3Tyr705
phosphorylation is not affected
The ErbB family member EGFR is over-expressed and
shows hyperactivity in many tumor types, including PDAC,
and is recognized as an important molecular target for
therapy. This aberrant activity of EGFR or other ErbB fa-
mily members activate a number of down stream targets
and may contribute to the constitutive STAT3Tyr705 phos-
phorylation found in cancer cells [15]. Hyperactivity of EGFR
or other growth factor pathways is also thought to play a role
in resistance to gemcitabine [19]. We evaluated the effect of
an EGFR inhibitor, AG1478, on the growth of PDAC
cell lines, PANC-1, UK Pan-1, MIA PaCa-2 and BxPC3.
AG1478 inhibited cell growth of the four PDAC cell lines in
a dose dependent manner; although, UK Pan-1 was less sen-
sitive compared to the other three cell lines (Figure 2A).
Only MIA PaCa-2 and BxPC3 cells showed significant
growth inhibition at 10 μM concentration of AG1478,
that was sufficient enough to inhibit the phosphorylation
of EGFRTyr1068 in all four cell lines tested (Figure 2B).Significant inhibition of growth of UK Pan-1 with
AG1478 required concentrations of 20 μM or higher
doses which are greater than that required for inhibiting
phosphorylation of EGFRTyr1068. This raises the possibility
that this growth inhibition may not be specific in regards
to inhibiting EGFR signaling (Figure 2A,B).
In order to determine the effect of AG1478 on the
phosphorylation of EGFR and potential down stream
signaling targets including STAT3, cell lines were stimu-
lated with EGF. Stimulation with EGF induced a robust,
but transient increase of EGFRTyr1068 phosphorylation,
as well as phosphorylation of down stream targets AKT
and ERKs in all of the cell lines tested (Figure 2B). In
cells treated with AG1478, EGFRTyr1068 phosphorylation
was inhibited at all time points analyzed, indicating the
effectiveness of AG1478. The transient increase in the
phosphorylation of AKT and ERKs following EGF stimu-
lation was also inhibited by treatment with AG1478.
EGF stimulation caused a transient reduction in the
basal level of phosphorylated STAT3Tyr705 at 1 h in three
of four cell lines, however, STAT3Tyr705 phosphorylation
returned to basal levels by 18 h. However, AG1478 treat-
ment did not inhibit the constitutive STAT3Tyr705 phos-
phorylation in EGF stimulated cells (Figure 2B). Treating
cells with AG1478 blocked the transient reduction of
phosphorylated STAT3Tyr705 following EGF induction.
This suggests the possibilities that EGFR signaling may
Figure 2 EGFR inhibitor AG1478 suppresses growth of human pancreatic cancer cells in vitro and constitutive STAT3Tyr705
phosphorylation is not suppressed by EGFR inhibitor AG1478 in PDAC cells. A, Exponentially growing PDAC cells were treated with
indicated concentrations of EGFR inhibitor AG1478 for 96 h and MTT assays were performed to measure cell growth. Data are presented as
% growth of control. Bars represent SD of eight replicates, and experiments repeated for three times. (*) = highly significant with a p < 0.001.
B, PDAC cells were serum deprived for 48 h and pre-treated with EGFR inhibitor, AG1478 (10 μM) for 4 h followed by stimulation with EGF
(50 ng/mL) for indicated periods of time in the presence or absence of EGFR inhibitor. Vehicle DMSO was used where EGFR inhibitor was not
used. Equal amounts of proteins were loaded and the blots were probed for phosphorylated and total forms of EGFR, STAT3, AKT and ERKs. As a
loading control, human β-actin levels are shown.
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an increase in the turnover of phosphorylated form of
STAT3Tyr705. More pertinent to the current study, these
observations suggest that constitutive STAT3Tyr705 phos-
phorylation does not require EGFR signaling in PDAC
cells. However, inhibiting EGFR activation with AG1478
affects other known down-stream signaling molecules
including phosphorylation of AKT and ERKs (Figure 2B)
thus proving the efficacy of inhibiting EGFR by AG1478
in the cell lines tested.Combination of AG1478 and gemcitabine does not cause
synergistic growth inhibition of PDAC cells in vitro and
does not block constitutive STAT3Tyr705 phosphorylation
Treatment with gemcitabine is reported to activate
EGFR [20] and therefore targeting EGFR might be
expected to mitigate pro-survival signaling induced by
this pathway [19]. We next determined the combined ef-
fect of AG1478 and gemcitabine on the growth of PDAC
cell lines in vitro. Cells were treated with AG1478 and
gemcitabine separately or in combination. Rates of
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treatment and a representative data is shown in Figure 3A.
For MIA PaCA-2 and BxPC3 cells, a significant increase in
growth inhibition was observed for combined therapy at the
lowest concentration of AG1478 used (10 μM) and required
concentrations of gemcitabine of at least 8 ng/ml
(Figure 3A). PANC-1 cells showed an increase of growth in-
hibition by gemcitabine when only combined with 20 and
40 μM dose of AG1478; however when compared to
gemcitabine treatment alone, the growth inhibition achievedFigure 3 Combination of AG1478 and gemcitabine does not cause sy
STAT3Tyr705 phosphorylation of PDAC cells. A, Exponentially growing PD
AG1478, gemcitabine or both together. MTT assays were performed to me
eight replicates, and the experiments were repeated three times. (*) = sign
remained significant at higher doses. B, Exponentially growing PDAC cells
(10 ng/ml), or both together. The blots were probed for phosphorylated an
levels are shown.by combining both agents was only incremental. In UK
Pan-1 cells, a significant effect was observed for combined
treatment when the highest concentration of AG1478
(40 μM) was used in combination and as seen with PANC-
1 cells, the combination treatment caused only a marginal
increase of growth suppression (Figure 3A). These observa-
tions suggest, although the combined treatments increased
growth inhibition, the effects were less than additive.
STAT3Tyr705 phosphorylation was not inhibited by
treating cells with either AG1478 or gemcitabine alone,nergistic growth inhibition and does not prevent constitutive
AC cells were exposed to indicated concentrations of EGFR inhibitor,
asure growth inhibition after 96 h of treatment. Bars represent SD of
ificant growth inhibition (p < 0.001) starts from this dose level and
were exposed to indicated concentrations of AG1478, gemcitabine
d total forms of EGFR and STAT3. As a loading control, human β-actin
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(40 μM) caused some inhibition (Figure 3B). Similarly,
combining both drugs had a minimal affect on the level of
STAT3Tyr705 phosphorylation except for BxPC3 where
higher doses of AG1478 (>20 μM) resulted in some reduc-
tion of STAT3Tyr705 phosphorylation (Figure 3B). It should
be noted that 10 μM concentration of AG1478 was suffi-
cient to inhibit phosphorylation of EGFR suggesting that
molecular affects requiring concentrations of AG1478
greater than 10 μM may represent off-target effects.
Inhibition of STAT3 by shRNA sensitizes PDAC cells to
gemcitabine in vitro
Because STAT3Tyr705 phosphorylation was maintained in
cells treated with AG1478 or gemcitabine, we hypothe-
sized that targeting STAT3 may serve as an independent
therapeutic target or may cause PDAC cells to be more
sensitive to gemcitabine. To inhibit STAT3, PDAC cells
PANC-1, UK Pan-1, MIA PaCa-2 and BxPC3 wereFigure 4 Inhibition of STAT3 by shRNA sensitizes PDAC cells to Gemc
cells were treated with indicated concentrations of gemcitabine for 96 h a
are presented as % growth of control. Bars represent SD of eight replicates
starts from this dose point and remains significant at higher dose levels. In
control and shSTAT3 clone cells. As a loading control, β-actin levels are shotransfected with a vector that expresses a shRNA against
STAT3 and individual stable clones were established
after antibiotic selection. These clones were tested for
the expression of STAT3 (data not shown) along with
control cells that express the vector alone. Control cells
and isogenically matched cells that express STAT3-
shRNA were treated with gemcitabine and were assessed
for growth by MTT assays. As shown in Figure 4, cells
that express shRNA against STAT3 were significantly
more sensitive to gemcitabine treatment as compared to
control cells. UK Pan-1 and PANC-1 cells showed a sig-
nificant dose dependent sensitivity to gemcitabine at
doses of 6 and 4 ng/ml respectively and knockdown of
STAT3 further increased their sensitivity as significant
growth inhibition was observed from 0.5 ng/ml and
greater. MIA PaCa-2 and BxPC3 cells were more resis-
tant to gemcitabine compared to UK Pan-1 and PANC-1
(Figure 4). Statistically significant growth inhibition was
observed for doses of gemcitabine from 25 ng/ml anditabine in vitro. PDAC cells and their respective STAT3-shRNA clone
nd MTT assays were performed to measure the rate of growth. Data
, repeated three times. (*) = significant growth inhibition (p < 0.001)
sets: Western blots showing differences in the expression of STAT3 in
wn.
Table 1 Percent apoptotic cells as measured by Caspase-3




UK Pan-1/Control 0.38 0.97 3.14
UK Pan-1/shSTAT3.cl.8 3.1 24.4 35.6
PANC-1/Control 0.01 0.01 .02
PANC-1/shSTAT3.cl.22 4.7 6.0 55.4
MIA PaCa-2/Control 0.06 0.06 0.07
MIA PaCa-2/shSTAT3.cl.2 2.6 5.5 10.0
BxPC3/Control 0.04 0.17 0.12
BxPC3/shSTAT3.cl.21 0.4 1.6 5.7
Table 2 Cell cycle analysis of cells treated with gemcitabine
% of cells at various phases of cell cycle
Cell line Untreated Gemcitabine (10 ng/ml)
G1 S G2 G1 S G2
MIA PaCa-2/Control 62.1 21.4 15.7 56.1 24.3 18.8
MIA PaCa-2/shSTAT3 47.5 32.9 17.8 70.3 13.9 14.9
BxPC3/Control 32.5 45.3 19.8 31.8 44.3 21.8
BxPC3/shSTAT3 38.2 33.8 25.1 70.0 15.0 13.6
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BxPC3 cells. Interestingly, knockdown of STAT3 in-
creased their sensitivity to gemcitabine to a level similar
to that seen for the more sensitive cell lines, UK Pan-1
and PANC-1 (Figure 4). Significant growth inhibition
was seen in STAT3 knock down cells at doses of 4 ng/
ml and 1 ng/ml for MIA PaCa-2 and BxPC3 cells re-
spectively. The relative expression levels of STAT3 as de-
termined by Western blot analyses are shown as insets
within the graph for the respective cell lines along with
β-actin as a loading control. We further evaluated
whether knocking down STAT3 sensitizes the cells to
EGFR inhibitor, AG1478. However, AG1478 treatment
of STAT3 knockdown cells did not cause a significant
increase in growth inhibition above that seen with con-
trol cells (Additional file 1: Figure S1). This result sug-
gests that targeting STAT3 enhances response to
gemcitabine-mediated growth suppression, but not to the
EGFR kinase inhibitor in the cell lines tested. Conversely,
over expressing STAT3 in PANC-1 cells, caused these cells
to be less sensitive to gemcitabine induced growth inhi-
bition. Vector transfected control cells showed a signifi-
cant growth inhibition at a dose of 4 ng/ml; whereas, the
STAT3 over expressing PANC-1 cells required a two fold
increase in the amount of gemcitabine (8 ng/ml) for sig-
nificant growth inhibition (Additional file 2: Figure S2).
This finding further supports the results of the knock
down experiments indicating that STAT3 plays a role in
reducing the response of PDAC cells to gemcitabine.
Increased sensitivity to gemcitabine in STAT3 shRNA cells is
mediated by the induction of apoptosis and growth arrest
Human PDAC cells that initially respond to gemcitabine
frequently develop resistance to treatment [21,22]. Diffe-
rent signaling pathways contribute to resistance against
apoptosis in pancreatic cancer cells [23]. Previous studies
indicate that mitochondria mediated apoptosis is impor-
tant for gemcitabine sensitivity. STAT3 is known to pro-
mote anti-apoptotic signals in many cancer types [24].
Because sensitivity to gemcitabine was enhanced in cells
where STAT3 was knocked down, we next tested whether
increased growth inhibition was accompanied with induc-
tion of apoptotic signaling. Control and STAT3-shRNA
expressing cells were treated with gemcitabine for 96 h
and then analyzed for caspase-3 activity by flow cytometry.
In control cells, gemcitabine treatment did not show
considerable caspase-3 activity, suggesting that they are
refractory to gemcitabine-mediated apoptosis at the con-
centrations used in this study. STAT3 knockdown cells
showed an appreciable increase in caspase-3 activity upon
treatment with gemcitabine (Table 1). However, knock-
down of STAT3 did not cause as much apoptosis in the
MIA PaCa-2 and BxPC3 cells treated with gemcitabine
(10.0% and 5.7% for 25 ng/mL of gemcitabine) comparedto the PANC-1 and UK Pan-1 cells (55.4% and 35.6% for
25 ng/mL of gemcitabine); (Table 1). This suggests that
the enhanced response to gemcitabine seen in MIA PaCa-
2 and BxPC3 cells is caused by a combination of growth
arrest and apoptosis. To address this possibility, cell cycle
analysis was performed in control and shSTAT3 knock-
down cells of MIA PaCa-2 and BxPC3 cells. Interestingly,
G1 arrest in shSTAT3 knockdown cells was greater after
treatment with gemcitabine. In MIA PaCa-2/shSTAT3
cells, the percentage of cells at G1 phase was 47.5%, and
treatment with gemcitabine increased the levels to 70.3%.
Similarly in BxPC3/shSTAT3 cells treatment with
gemcitabine increased the percentage of cells in G1 phase
to 70% as compared to untreated cells showing only 38.2%
cells. The G1 phase in the MIA PaCa-2 and BxPC3 vector
control cells was not appreciably affected by treatment
with gemcitabine (Table 2).
Inhibition of STAT3 by shRNA suppressed the growth of
tumors in vivo and increased sensitivity to gemcitabine
To further validate the data observed in vitro, an
orthotopic mouse pancreatic cancer model was utilized
[25] to assess STAT3 as a target for therapy in vivo.
Control BxPC3/Vector cells and isogenically matched
BxPC3 cells expressing shSTAT3 (BxPC3/shSTAT3)
were implanted orthotopically. Tumors derived from
mice implanted with control BxPC3/Vector cells deve-
loped rapidly and were measured four weeks after
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BxPC3/shSTAT3 cells showed a delay in tumor develop-
ment and therefore tumors in these animals were allowed
to grow until week ten. Treatment with gemcitabine sig-
nificantly (p < 0.0001) reduced the growth of tumors from
BxPC3/shSTAT3 group of animals as compared to control
group of animals treated with gemcitabine. These experi-
ments were repeated several times although with a fewer
number of animals. The observations were similar in all
the repeat experiments, i.e., the control (BxPC3/Vector)
group of animals always formed large palpable tumors be-
tween weeks four and six. Tumor growth was delayed in
mice implanted with BxPC3/shSTAT3 cells by an add-
itional 4–6 weeks compared to BxPC3/Vector (data not
shown for repeat experiments).
Tumor tissues were further analyzed by immunohisto-
chemistry (IHC) for STAT3 and Ki-67. Nuclear expression
of Ki-67 was used as a marker for proliferation and STAT3
staining was used to confirm that STAT3 was knocked
down in tumors from the BxPC3/shSTAT3 group.Figure 5 Inhibition of STAT3 suppressed the growth of tumors in vivo
orthotopically implanted in a mouse model. Both group of animals were tr
three days until sacrifice. Primary tumors were surgically removed at week
group of animals. The isolated tumors were weighed to measure the grow
group. Formalin fixed tumor tissue sections were analyzed for nuclear Ki-67
isolated from the tumors of BxPC3/Vector and BxPC3/shSTAT3 group of an
β-actin and STAT3 are shown as a loading control.Tumors in the control group (BxPC3/Vector) showed
49.5% Ki-67 positive cells and treatment with gemcitabine
reduced the expression level of Ki-67 to 37.3% (Figure 5B).
In tumors derived from the mice implanted with BxPC3/
shSTAT3 cells, nuclear expression of Ki-67 was signifi-
cantly (p < 0.01) reduced to 29.0% as compared to 49.5%
for BxPC3/Vector group. Treatment with gemcitabine fur-
ther and significantly (p < 0.05) reduced the levels to
14.6% in the STAT3 knockdown group (Figure 5B). As
expected, tumors derived from BxPC3/shSTAT3 group of
animals showed reduced expression of STAT3 (Figure 5C)
as determined by immunohistochemistry. Total cellular
proteins were isolated from the tumors of both groups
(BxPC3/Vector and BxPC3/shSTAT3) and subjected to
Western blot analysis to assess the levels of both phos-
phorylated and total forms of STAT3. Consistent to the
observations made from immunohistochemistry, tu-
mors from BxPC3/shSTAT3 showed diminished levels
of STAT3. Similar to STAT3, the phosphorylated levels
of STAT3Tyr705 were also reduced as shown in the. A, BxPC3/Vector and shSTAT3 expressing (BxPC3/shSTAT3) cells were
eated with gemcitabine (20 mg/kg body weight) or saline IP every
4 and week 10 respectively for BxPC3/Vector and BxPC3/shSTAT3
th of tumors and a representative data is shown for 10 animals in each
(B) and STAT3 (C) by immunohistochemistry. D, Total cellular proteins
imals were analyzed by Western blot for the expression of STAT3Tyr705.
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(Figure 5D).
Discussion
Treatment with gemcitabine continues to be the stan-
dard mode of therapy either as a single agent or in com-
bination with an EGFR inhibitor; however, PDAC still
remains a great challenge in oncology as the rate of mor-
tality nears the rate of incidence [1]. In this study, we
sought to identify pro-survival pathways that are acti-
vated in the presence of gemcitabine and an EGFR in-
hibitor, AG1478, using PDAC cell line models.
Interestingly, STAT3Tyr705 phosphorylation was not
inhibited by treatment with AG1478 except for, a partial
inhibition that was observed in BxPC3 cells treated for
96 h with higher concentrations of AG1478. STAT3Tyr705
phosphorylation is considered to be a down stream target
of EGFR signaling in some cell types [26]. However, other
studies showed that inhibiting EGFR signaling did not
affect STAT3Tyr705 phosphorylation [27-29]. Skin biopsies
of patients treated with the EGFR inhibitor Gefitinib
showed a decreased EGFR activation that was associated
with an increase in STAT3Tyr705 phosphorylation [28]. In a
majority of the HNSCC cells lines tested, inhibition of
EGFR signaling by AG1478 did not affect the overall
STAT3Tyr705 phosphorylation levels, while EGFR, ERKs
and STAT3Ser727 phosphorylation was inhibited [29]. In
agreement with these latter studies, the data presented
here indicates that constitutive STAT3Tyr705 phosphory-
lation does not require EGFR signaling in the four human
PDAC cell lines that were examined. As anticipated, treat-
ment with AG1478 of the four PDAC cell lines used in
this study did show inhibition of phosphorylation of
EGFR, AKT and ERKs (Figure 2B). Thus the growth sup-
pressive effect of AG1478 may be attributable to a reduc-
tion of the phosphorylation of AKT or ERKs, which are
also known to play a role in tumor progression. However,
even after effective inhibition of EGFR signaling, the pres-
ence of constitutive STAT3Tyr705 phosphorylation may
decrease the response to chemotherapy by inducing pro-
survival pathways. Similar to this observation, treatment
of cells with gemcitabine either alone (Figure 1) or in com-
bination with AG1478 did not affect the constitutive
STAT3Tyr705 phosphorylation (Figure 3B). The presence of
constitutive phosphorylation of STAT3Tyr705 following
treatment with AG1478 or gemcitabine prompted us to
investigate whether inhibiting STAT3 would increase the
sensitivity of PDAC cells to chemotherapy.
Interestingly, PDAC cells with knockdown of STAT3
demonstrated a similar exponential growth rate as the
control cells in vitro. However, PDAC cells with STAT3
knocked down showed a decreased colony forming ability
when plated at low density suggesting a reduced onco-
genic phenotype (data not shown). Cells where STAT3was knocked down showed a significant increase of
growth inhibitory response to gemcitabine (Figure 4).
STAT3 knockdowns of PANC-1 and UK Pan-1 cells
showed significant growth inhibition from 0.5 ng/ml dose
of gemcitabine as compared to 4 and 6 ng/ml of gem-
citabine required to cause significant growth inhibition of
their respective control cells. BxPC3 and MIA PaCa-2 cells
showed a greater resistance to gemcitabine compared to
PANC-1 and UK Pan-1. Knockdown of STAT3 in the
gemcitabine resistant PDAC cell lines (BxPC3 and MIA
PaCa-2) resulted in a significant increase of growth sup-
pression. Control MIA PaCa-2 and BxPC3 cells required
25 and 8 ng/ml of gemcitabine respectively to inhibit
growth significantly; whereas 4 and 1 ng/ml of gemci-
tabine was needed to cause significant growth inhibition
in cells where STAT3 was knocked down (Figure 4). The
response of BxPC3 and MIA PaCa-2 cells where STAT3
was knocked down was comparable to the control group
of PANC-1 and UK Pan-1 cells. In addition, the sensitivity
to gemcitabine achieved by knocking down STAT3 was
much greater than that observed by combining AG1478
and gemcitabine. It is interesting that cell lines PANC-1
and UK Pan-1 possess intact TGF-β signaling components
while cell lines BxPC3 and MIA PaCa-2 lack TGF-β sig-
naling due to lack of Smad4 or because of transcriptional
repression of TGF-β type II receptor, respectively [30]. We
previously observed that restoration of Smad4 in PDAC
cells suppressed the levels of STAT3Tyr705 phosphorylation
and reversed the TGF-β mediated invasion [25]. Add-
itional studies are needed to determine whether inhibiting
STAT3 may be of further therapeutic benefit in cells that
lack intact TGF-β signaling.
Over-expression of STAT3 reduced the gemcitabine
induced growth suppression in PANC-1 cells (Additional
file 2: Figure S2). This observation further supporting
the notion that STAT3 play a role in mediating reduced
sensitivity to gemcitabine of PDAC cells.
A recent study [18] showed that suppression of RON
sensitized PDAC cells to gemcitabine. The observations
from this study showed PDAC cells used in this study
expressed varying levels of RON expression, but treatment
with gemcitabine did not appreciably alter RON levels
(Figure 1). However, inhibition of STAT3 in these PDAC
cells did sensitize them to gemcitabine. Thus, inhibiting
STAT3 in high RON expressing cells may provide a novel
approach for enhancing tumor response to gemcitabine.
Human PDAC cells are known to have inherent resis-
tance or to develop resistance against gemcitabine medi-
ated apoptosis [31]. Treatment with gemcitabine did not
induce considerable pro-apoptotic signals in the cell lines
tested in this study. However, STAT3 knockdown in
PANC-1 and UK Pan caused a dramatic increase in
caspase-3 activity. Whereas, in MIA PaCa-2 and BxPC3
cells, knockdown of STAT3 resulted in only a modest
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citabine, but was accompanied with an increase in G1 cell
cycle arrest (Tables 1 and 2).
While knockdown of STAT3 rendered PDAC cells
sensitive to gemcitabine mediated killing, these cells did
not show enhanced growth suppression when treated
with EGFR inhibitor AG1478. Further studies are needed
to verify what other targets are responsible for this
phenomena.
To further validate these in vitro findings, mice were
orthotopically implanted with BxPC3 control cells or
with the isogenically matched BxPC3/shSTAT3 cells.
Mice implanted with control cells and treated with saline
had large tumors by week four. Mice implanted with
control cells and treated with gemcitabine had smaller
tumors at this point, confirming that these tumors
responded to gemcitabine in vivo. However, mice im-
planted with Bx/shSTAT3 cells did not show palpable
tumors by week four; tumors similar in size to the con-
trol group did not develop until week ten. Treatment
with gemcitabine resulted in significantly smaller tumors
in mice implanted with shSTAT3 cells indicating that a
combination of gemcitabine and knockdown of STAT3
results in a significant reduction of tumor growth over
either one alone. A multitude of signaling events by
STAT3 may converge to enhance tumor progression
with increased resistance against chemotherapeutic
agents. The findings of this study suggest that constitutive
STAT3Tyr705 activation may play an important role in pan-
creatic oncogenesis that is independent of EGFR signaling
and thus may be an important biologic target. Moreover,
these data suggest that targeting STAT3 may increase
response to gemcitabine and may reverse, at least in
part, resistance to this chemotherapeutic agent. Currently
there are great efforts to develop clinically relevant inhibi-
tors for STAT3 [14,32] and thus these new agents should
be tested, as they become available, in combination with
current standard chemotherapy.
Conclusions
The observations of this study demonstrate that onco-
genic constitutive STAT3Tyr705 phosphorylation is not
affected by treatment of PDAC cells with gemcitabine or
AG1478 either alone or in combination. Both the agents
together did not induce synergistic growth inhibition
suggesting that STAT3 may be a target to enhance the
overall response to chemotherapy. Knockdown of
STAT3 in PDAC cells enhanced their response to
gemcitabine mediated cell growth inhibition in part due
to increased pro-apoptotic activity as evidenced by an
induction of caspase-3 activity or an increase of G1 cell
cycle arrest. However, knockdown of STAT3 did not en-
hance the growth suppressive activity of an EGFR inhibi-
tor, AG1478. In vivo orthotopic animal studies furtherconfirmed that STAT3 could be a viable target in PDAC
cells to increase the sensitivity to gemcitabine. Knocking-
down STAT3 significantly reduced the tumor burden as
evidenced by a slower tumor progression and further re-
duced the growth of tumors that is associated with a
reduction of Ki-67 positive cells. This study suggests
that STAT3 is to be considered a viable target to en-
hance chemotherapeutic response of PDAC cells.Methods
Cell lines
Established human PDAC cell lines PANC-1, BxPC3 and
MIA PaCa-2 used in this study were purchased from
American Type Culture Collection (Manassas, VA). UK
Pan-1 cell line was established in our laboratory [33].
Cell lines (PANC-1, UK Pan-1 and MIA PaCa-2) were
grown in DMEM (Cell Grow-Mediatech) and BxPC3
cells were grown in RPMI medium (InVitrogen). Both
types of media were supplemented with 10% fetal bovine
serum (Cell Grow-Mediatech).Reagents
Commercially available EGFR inhibitor AG1478 was
purchased from EMD Biosciences and gemcitabine was
purchased from LTK Corporation. AG1478 was solubi-
lized in DMSO and gemcitabine was dissolved in PBS.
For animal injections, pharmaceutical grade gemcitabine
(200 mg vial for injection) was used (Dr. Reddy’s Labora-
tories, Limited, India).Cell growth assays
The growth rate of AG1478 or gemcitabine treated
cells was determined by 3-(4,5-dimethylthiazol-2-yl)-2,
5-diphenyltetrazolium bromide (MTT) assays as descri-
bed previously [30]. Exponentially growing cells (1–2 × 103)
were plated in 96-well plates. Cells were treated with indi-
cated concentrations of either gemcitabine or AG1478 or
treated with both agents in combination. MTT assays were
performed after 96 h of treatment. At the end of treatment
period, cells were stained with 0.5 mg/mL MTT (Sigma
Chemical Company) at 37°C for 2 h. MTT containing
medium was aspirated and the cells were solubilized in
200 μL of DMSO. Colorimetric determination was done
with a Molecular Devices plate reader. The data are repre-
sented as the mean value of eight wells per treatment
group and the experiments were repeated a minimum of
three times. To evaluate differences between treatment
groups, analysis of variance (ANOVA) combined with
Tukey’s multiple range test was performed (GraphPad
Software, Inc.) and considered statistically significant when
p < 0.001.
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To knockdown STAT3, cells were transfected with Sure
Silencing shRNA-STAT3 plasmid (SuperArray Bioscience
Corporation) according to manufacturer’s suggestion
using FuGene 6 (GE) transfection reagent as previously
reported [25]. Cells were cultured further and selected in
medium containing 620 μg/mL G418 for PANC-1, UK
Pan-1 and MIA PaCa-2 cells or 200 μg/mL G418 for
BxPC3 cells. Individual G418-resistant colonies were iso-
lated during drug selection and established as individual
clones for further analysis. To over-express STAT3,
PANC-1 cells were transfected with STAT3 cDNA (a kind
gift from Dr. Richard Jove’s lab) using FuGene 6 (GE) and
G418-resistant clones were isolated and established as in-
dividual clones for further studies.
Western immunoblots
Total cellular proteins were extracted by using Laemmli
buffer and Western immunoblots were done as de-
scribed previously [30]. Cells were harvested at indicated
time points after treatment with AG1478 or gemcitabine
along with appropriate controls. Seventy micrograms of
protein lysates were electrophoresed on an 8% SDS-
polyacrylamide gel and then transferred to Hybond-P,
polyvinylidene difluoride membrane (BioRad). Primary
antibodies for EGFR, β-actin, STAT3, phosphorylated
STAT3Tyr705 and RON were from Santa Cruz Biotech-
nology; phosphorylated EGFRTyr1068 ERKs, phosphory-
lated ERKsThr202/Tyr204, AKT, phosphorylated AKTSer473
were from Cell Signaling Technology. The blots were
probed with specific antibodies and detected by en-
hanced chemiluminescence methods (Pierce).
Active Caspase-3 assay and cell cycle analysis by flow
cytometry
Cells undergoing apoptosis was determined by flow cy-
tometry using a BD Pharmingen active Caspase-3 FITC
kit. Cells were treated with indicated concentrations of
gemcitabine for 96 h and processed for flow cytometric
analysis per manufacturer’s suggestion. Data are pres-
ented as the percent of apoptotic cells. Exponentially
growing MIA PaCa-2 and BxPC3 cells were treated with
gemcitabine (10 ng/mL) for 24 h and cell cycle analysis
was performed by flow cytometry. The above mentioned
flow cytometry experiments were conducted with
FACSCalibur (Becton Dickinson Immunocytometry
Systems Inc, San Jose) at our institutional core flow cy-
tometry facility.
Orthotopic pancreatic cancer mouse model
4–5 week-old athymic nude mice were purchased from
Harlan Corp. Mice were housed and maintained in ac-
cordance with the standards of The University of Texas
Health Science Center at San Antonio Animal Care andUse Committee. BxPC3/Vector or BxPC3/shSTAT3 cells
were grown to 80% confluence, trypsinized and re-
suspended in PBS, and then 1 × 106 cells/50 μL were
injected directly into the pancreas of anesthetized mice
[25]. Two weeks after implantation, mice were injected
with either gemcitabine (20 mg/kg) or saline IP every
3 days until sacrifice. Primary tumors were surgically re-
moved and weighed. Statistical analysis was determined
by t-test (GraphPad Software, Inc.). Statistical signifi-
cance between control and gemcitabine treated groups
was considered when p < 0.05.
Immunohistochemistry
Tumors derived from control and experimental groups
were fixed in formalin. The paraffin embedded tumor tis-
sue sections were processed at our institutional core facil-
ity, Histology and Pathology Laboratory at the University
of Texas Health Science Center at San Antonio for the ex-
pression of Ki-67 and STAT3 per standard procedures.
Two tumors were analyzed from each treatment group for
the analysis of Ki-67 positive staining. Digital image ana-
lysis was carried out to determine the nuclear staining
levels by using “ImmunoRatio”, a web based analysis soft-
ware [34]. A minimum of ten microscopic field areas were
analyzed for each tumor slide and the data were plotted as
percent positive cells for Ki-67 staining. Statistical signifi-
cance (p < 0.05) was evaluated by the ANOVA combined
with Tukey’s multiple range test (GraphPad Software, Inc.).
Additional files
Additional file 1: Figure S1. AG1478 induced growth inhibition of
PDAC cells is not altered by knocking down STAT3. Exponentially
growing PDAC cells and their respective shSTAT3 clones were treated
with the indicated concentrations of EGFR inhibitor, AG1478. MTT assays
were performed to measure growth after 96 h of treatment.
Additional file 2: Figure S2. STAT3 over-expression decreases
gemcitabine mediated growth inhibition of PANC-1 cells. PANC-1 control
cells expressing an empty vector (C) or PANC-1 cells expressing STAT3
cDNA (OE) cells were treated with indicated concentrations of
gemcitabine for 96 h and MTT assays were performed to analyze the
growth. *, Significant growth inhibition (p < 0.001) starts from this dose
point and beyond. Inset: Western blot showing the over-expression of
STAT3 as compared with control cells. Human β-actin is used as a
loading control.
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